Last updated: September 24, 2026
Donepezil is a mature, high-volume generic drug with limited active-ingredient exclusivity but continuing commercial opportunities in formulation development, taste masking, orally disintegrating tablets, high-dose tablets, oral liquids, and manufacturing efficiency. The strongest opportunities are low-cost, regulatory-efficient products that improve swallowability, dose flexibility, stability, or patient adherence without changing systemic exposure.
What is the current FDA and commercial status of donepezil?
Donepezil hydrochloride is an acetylcholinesterase inhibitor approved for the symptomatic treatment of mild, moderate, and severe Alzheimer’s disease. The reference product is Aricept, originally developed and commercialized by Eisai and Pfizer. The FDA approved immediate-release donepezil tablets in 1996, orally disintegrating tablets in 2004, and the 23 mg tablet in 2010. [1,2]
| Product |
Strengths |
Dosage form |
Commercial status |
| Aricept |
5 mg, 10 mg |
Immediate-release tablet |
Reference product; generic competition |
| Aricept ODT |
5 mg, 10 mg |
Orally disintegrating tablet |
Generic ODT competition |
| Aricept 23 mg |
23 mg |
Immediate-release high-dose tablet |
Generic competition subject to product-specific FDA requirements |
| Donepezil hydrochloride generics |
5 mg, 10 mg, 23 mg |
Tablets and ODTs |
Multiple ANDA-approved products |
| Donepezil oral solution |
Commonly 1 mg/mL equivalent concentration |
Oral liquid |
Limited but commercially relevant niche |
Donepezil has no biologic component, so biosimilar risk is not applicable. Competitive pressure comes from conventional generics, authorized or branded generics, alternative dosage forms, and pharmacy supply contracts.
The original compound and core product protections have expired or no longer prevent routine generic entry in the United States. Current commercial barriers are primarily regulatory, manufacturing, formulation, supply-chain, and market-access barriers rather than broad compound exclusivity.
When did donepezil lose exclusivity?
Donepezil’s principal small-molecule and reference-product exclusivity periods have expired. Generic entry began in the United States in 2010 for several immediate-release strengths after loss of core protection for the reference product. [3]
The commercial position is now defined by:
- FDA approval status for each dosage form and strength.
- Orange Book patent listings applicable to specific products.
- Paragraph IV certifications filed against any remaining listed patents.
- Product-specific bioequivalence requirements.
- Manufacturing cost and supply reliability.
- Pharmacy benefit manager and wholesaler purchasing decisions.
The 23 mg product has had a more concentrated patent and regulatory history than the 5 mg and 10 mg tablets. Developers should assess current Orange Book listings and litigation records before selecting a launch date or making a paragraph IV strategy. The relevant question is usually not whether donepezil as a molecule remains protected, but whether a particular high-dose formulation, use, or delivery system has a live, enforceable claim.
What patents protect donepezil products?
The original donepezil compound patents no longer create a material barrier to ordinary generic tablets. Later protection focused on product-specific formulations, dosage strengths, methods of use, and delivery formats.
Orange Book-listed protection
The FDA Orange Book remains the controlling public source for patents listed against approved reference products. Relevant review categories include:
| Patent category |
Relevance to donepezil |
| Compound patent |
Historically important; no longer a routine barrier to generic entry |
| Composition patent |
May cover a particular formulation or excipient system |
| Method-of-use patent |
May address a disease stage, dose, or treatment regimen |
| High-dose product patent |
Particularly relevant to 23 mg products |
| ODT formulation patent |
May cover rapid disintegration, taste masking, or manufacturing parameters |
| Manufacturing patent |
More relevant to process differentiation than routine ANDA entry |
A generic applicant may certify under Paragraph I, II, III, or IV depending on the status of the listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. It can create litigation risk and, for the first qualifying filer, potentially provide 180-day generic exclusivity under the Hatch-Waxman framework. [4]
Because donepezil is mature, the most practical patent strategy is often defensive rather than exclusionary. A manufacturer can pursue independent formulation claims around taste masking, granulation, excipient ratios, coating systems, or process controls. Those claims are unlikely to restore broad molecule-level exclusivity but can protect a differentiated product or licensing position.
What excipient strategy is best for immediate-release donepezil tablets?
The baseline strategy is a low-cost, robust immediate-release tablet using excipients with established regulatory histories and broad supplier availability.
Core excipient functions
| Formulation function |
Suitable excipient classes |
Strategic objective |
| Dilution |
Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate |
Achieve tablet weight and content uniformity |
| Binding |
Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose |
Improve granule and tablet strength |
| Disintegration |
Croscarmellose sodium, crospovidone, sodium starch glycolate |
Control breakup and dissolution |
| Lubrication |
Magnesium stearate, sodium stearyl fumarate |
Improve ejection and manufacturing throughput |
| Glidant |
Colloidal silicon dioxide |
Improve powder flow |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Improve appearance, handling, and light protection |
Donepezil hydrochloride is generally formulated at low drug-loading levels for the 5 mg and 10 mg strengths. Content uniformity and segregation control are therefore more important than raw material cost alone. Direct compression can reduce manufacturing steps, but it requires reliable powder flow, narrow particle-size distribution, and appropriate blend segregation controls.
Wet granulation is more tolerant of poor flow and low-dose distribution problems. It can improve tablet robustness but raises process complexity, drying requirements, and scale-up risk. Dry granulation can be attractive where moisture sensitivity or shorter processing time is important.
A commercially efficient platform can use a common excipient architecture for 5 mg and 10 mg tablets, with strength differentiation achieved through API quantity, tablet weight, color, and tooling. This reduces validation and inventory costs.
What excipients are appropriate for donepezil orally disintegrating tablets?
Donepezil ODTs are the clearest excipient-driven commercial opportunity because the product must balance rapid disintegration, mechanical strength, dose uniformity, mouthfeel, and taste.
ODT formulation priorities
An effective donepezil ODT should:
- Disintegrate rapidly without water.
- Mask the bitter or medicinal taste of donepezil.
- Resist breakage during packaging and distribution.
- Maintain dissolution comparable to the reference product.
- Avoid excessive friability and powder generation.
- Support high-throughput tableting or validated freeze-drying.
Common ODT excipient systems include:
- Mannitol for cooling mouthfeel, bulk, and water-soluble dissolution.
- Microcrystalline cellulose for structure.
- Crospovidone or croscarmellose sodium for rapid disintegration.
- Low-substituted hydroxypropyl cellulose for wicking and breakup.
- Aspartame, sucralose, acesulfame potassium, or saccharin for sweetness.
- Flavors such as mint, vanilla, berry, or citrus.
- Colloidal silicon dioxide for flow.
- Magnesium stearate or sodium stearyl fumarate for lubrication.
Mannitol-based formulations are commercially attractive because they can improve mouthfeel while supporting rapid dissolution. However, excessive lubricant levels can delay wetting and dissolution. A low-force compression design may improve disintegration but can create unacceptable friability.
Taste masking is the principal technical challenge. Simple sweetener addition may not be sufficient because the drug can dissolve rapidly in saliva. More durable approaches include polymer coating of drug particles, ion-exchange resin complexes, lipid-based barriers, and pH-dependent taste-masking systems.
For an ANDA product, taste masking cannot compromise drug release or produce meaningful pharmacokinetic differences. Comparative dissolution across multiple pH conditions is important, particularly where the reference ODT uses a distinct manufacturing process.
What formulation strategy fits donepezil 23 mg?
The 23 mg strength creates different development constraints from 5 mg and 10 mg products. The dose is high enough to create tablet-size, swallowability, hardness, and disintegration challenges.
A 23 mg formulation should prioritize:
- High-dose content uniformity.
- Acceptable tablet size.
- Mechanical strength during coating and packaging.
- Rapid but controlled disintegration.
- Low friability.
- Reliable dissolution across commercial equipment.
- Clear differentiation from 10 mg tablets to reduce medication errors.
Direct compression may be feasible when the API and excipient blend have consistent flow and compactibility. Roller compaction can improve flow and reduce segregation, but it may produce harder granules that delay disintegration. Wet granulation can improve uniformity but increases manufacturing cost.
The 23 mg tablet also presents a patient-adherence issue. Many patients with Alzheimer’s disease have dysphagia, and a high-dose tablet can be difficult to swallow. This creates a potential commercial opportunity for a smaller-volume, multiparticulate, dispersible, or liquid product, subject to FDA approval and bioequivalence requirements.
What commercial opportunities exist for donepezil excipients and formulations?
Orally disintegrating tablets
ODTs remain the most direct opportunity. Product differentiation can come from:
- Faster disintegration.
- Better taste masking.
- Lower friability.
- Smaller tablet size.
- More stable blister packaging.
- Improved handling for caregivers.
- Consistent performance under humidity stress.
The commercial value is greater in institutional care, long-term-care pharmacies, and caregiver-managed medication systems than in purely price-driven retail channels.
Oral liquids
Donepezil oral liquids can address swallowing difficulty and dose titration. Key excipient issues include:
- API solubility and pH control.
- Preservative effectiveness.
- Microbial control.
- Sweetness and flavor.
- Sedimentation or precipitation.
- Container compatibility.
- Accurate dosing-device performance.
Potential systems include aqueous solutions, buffered liquids, and suspensions. A true solution is preferable for dose uniformity, but it may impose pH, solubility, and stability constraints. A suspension can broaden formulation options but requires redispersibility validation and clear labeling.
A liquid product may have value in pediatric investigational use, although donepezil’s principal approved market is elderly patients. Its strongest commercial rationale is therefore dysphagia management and caregiver administration rather than pediatric positioning.
Sprinkle or multiparticulate products
Multiparticulates could allow administration by sprinkling onto soft food. The development burden is higher because the sponsor must demonstrate:
- Uniform distribution in the food vehicle.
- Stability after mixing.
- Acceptable taste.
- No unacceptable chewing-related dose release.
- Product performance through the intended administration route.
This approach can support nursing-home and home-care use but may require a new regulatory strategy rather than a straightforward tablet generic.
Excipient and process licensing
Licensing opportunities may arise around:
- Taste-masked donepezil particles.
- Direct-compression platforms for low-dose APIs.
- High-dose mini-tablet technology.
- Moisture-resistant ODT packaging.
- Resin-complexed or coated multiparticulates.
- Ready-to-use granulation systems.
- Pediatric or dysphagia-oriented oral liquids.
The strongest licensing candidates are technologies that solve a documented product problem and can be transferred without requiring extensive clinical redevelopment.
How strong is the donepezil formulation patent estate?
The formulation patent estate is weaker than the estate surrounding newer branded drugs because donepezil has been generic for many years. A new formulation patent can still have value if it claims a narrow, reproducible, commercially relevant feature.
Patent strength depends on:
| Factor |
Stronger position |
Weaker position |
| Claim scope |
Defined composition and process relationship |
Broad functional claim |
| Prior art |
Limited disclosure of the exact system |
Numerous ODT and taste-masking precedents |
| Reproducibility |
Clear excipient ranges and process controls |
Unpredictable performance |
| Clinical benefit |
Demonstrated adherence or administration benefit |
Only minor manufacturing advantage |
| Design-around risk |
Multiple interdependent claim elements |
Single excipient substitution defeats claim |
| Regulatory linkage |
Listed patent tied to approved product |
Unlisted or non-product-specific patent |
For donepezil, claims based only on common excipients are vulnerable to obviousness and design-around arguments. Stronger claims would connect a defined excipient architecture with measurable performance, such as rapid disintegration, stable taste masking, controlled dissolution, or improved storage stability.
Which companies are challenging or competing with donepezil?
Competition is fragmented among generic manufacturers and contract manufacturers. Major generic participants have included Teva, Sandoz, Dr. Reddy’s, Lupin, Aurobindo, Sun Pharma, Zydus, Torrent, and other regional suppliers, although product availability varies by strength and dosage form.
The relevant competitive groups are:
- Large generic manufacturers competing on price and supply reliability.
- Regional manufacturers serving institutional and government tenders.
- Specialty companies developing ODT, liquid, or dysphagia-focused products.
- Contract development and manufacturing organizations supplying private-label products.
- Excipient suppliers offering co-processed excipients and taste-masking platforms.
The market favors suppliers that can maintain uninterrupted API and excipient supply. Donepezil’s low unit price makes manufacturing yield, packaging cost, and inventory turns more important than premium branding.
What generic launch risks exist for donepezil?
A generic launch can proceed through an ANDA where the proposed product matches the reference product in active ingredient, dosage form, strength, route, and applicable performance characteristics. Key risks include:
- Failure of dissolution matching.
- ODT taste or disintegration differences.
- Content-uniformity failures at low drug loading.
- Packaging-related moisture degradation.
- 23 mg tablet size and mechanical-strength problems.
- Orange Book patent disputes.
- API supplier qualification failure.
- Commercial price erosion.
- Wholesaler and pharmacy substitution limits.
- Manufacturing-site inspection findings.
For a differentiated dosage form, the sponsor must avoid assuming that formulation novelty creates automatic commercial protection. FDA approval, patent enforceability, reimbursement, and pharmacy substitution are separate issues.
What is the revenue exposure and commercial outlook?
Donepezil is a mature, low-price product. Revenue exposure is concentrated in volume rather than price. A conventional 5 mg or 10 mg tablet launch may produce limited margin unless the manufacturer has scale, efficient procurement, and reliable supply.
Higher-value opportunities include:
- ODTs with caregiver and institutional demand.
- 23 mg products with limited supplier competition.
- Oral liquids for dysphagia.
- Private-label products for long-term-care channels.
- Regional markets with lower generic penetration.
- Contract manufacturing of differentiated dosage forms.
- Excipient platforms that can be reused across other bitter, low-dose APIs.
The commercial case is strongest when donepezil is used as a platform product for a broader portfolio rather than as a standalone premium generic.
What geographic markets offer opportunities?
The United States has high generic penetration and significant price competition. Europe and other regulated markets provide opportunities for ODT and oral-liquid products, but national reimbursement, substitution rules, and reference-product requirements differ.
Emerging markets may offer greater unmet demand for convenient administration formats, but regulatory pathways, local manufacturing requirements, and price controls can reduce returns. A global product strategy should separate:
- United States ANDA and Orange Book requirements.
- European generic or hybrid applications.
- Country-specific bioequivalence standards.
- Local excipient permissions.
- Packaging and labeling requirements.
- Government tender economics.
Excipient selection should use globally accepted materials where possible. A formulation relying on a regionally restricted colorant, sweetener, or preservative can increase registration complexity.
Key Takeaways
- Donepezil’s core molecule-level exclusivity has expired, and generic competition is established.
- The most practical opportunities are ODTs, oral liquids, high-dose 23 mg products, and caregiver-oriented dosage forms.
- Taste masking is the central formulation challenge for ODTs.
- Low-dose 5 mg and 10 mg tablets require strong segregation and content-uniformity control.
- The 23 mg product requires separate attention to tablet size, mechanical strength, dissolution, and swallowability.
- Formulation patents can provide niche protection but are vulnerable when based only on conventional excipients.
- Commercial returns depend more on manufacturing efficiency, supply reliability, and channel access than on premium pricing.
- Excipient technologies with cross-product applicability have greater licensing value than a single-product formulation alone.
FAQs About Donepezil Excipient and Formulation Strategy
What is the best disintegrant for donepezil ODTs?
Crospovidone and croscarmellose sodium are common starting options. The best choice depends on compression force, tablet porosity, taste-masking coating, and target dissolution profile.
Can donepezil be formulated as a liquid?
Yes. A liquid may be developed as a solution or suspension, with solubility, preservative effectiveness, microbial control, dosing accuracy, and taste as the principal development issues.
Is mannitol suitable for donepezil orally disintegrating tablets?
Yes. Mannitol is widely used in ODTs because it provides bulk, water solubility, and a cooling mouthfeel. Its concentration must be balanced against tablet strength and drug-release performance.
Does donepezil have biosimilar competition?
No. Donepezil is a chemically synthesized small molecule. Competition is through generic drugs, not biosimilars.
Is a new donepezil ODT automatically protected by a patent?
No. Patentability depends on novelty, nonobviousness, claim scope, enablement, and the specific formulation or process. Common excipient combinations may not provide strong protection.
References
-
U.S. Food and Drug Administration. (1996). Aricept (donepezil hydrochloride) prescribing information.
-
U.S. Food and Drug Administration. (2010). Aricept 23 mg (donepezil hydrochloride) prescribing information.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, donepezil hydrochloride products.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. Orange Book.
-
U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.
-
U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.
